omparison of the Impact of Atracurium and Cisatracurium on the Neutrophil-To-Lymphocyte Ratio in Addition to Hemodynamic Changes during Anesthesia Induction
,
Abstract
Background: Muscle relaxants are used for two general purposes. One is to ease endotracheal intubation, and the other is provide surgical relaxation.
This study has been designed with the aim of assessing the impact of atracurium and cisatracurium on patients at the anesthesia induction and the neutrophil to lymphocyte ratio.
Methods: This is a randomized clinical trial that was performed in 2022-2023 in Kashani hospital in Isfahan, Iran on patients that were candidates for elective surgery under general anesthesia by atracurium or cisatracurium. A total number of 80 patients entered and were randomized into two group’s one receiving group atracurium 0.5mg/kg, and other group received cisatracurium 0.15mg/kg over 60 seconds as NMB. Blood sample were taken base time, after 3, and 20 minutes following intubation. Qualitative data is reported as frequency with percentage. And quantitative data as average with standard deviation. Statistical analysis was done using SPSS version 25. Qualitative data were analyzed using chi-square tests and quantitative data using independent T test. Significance level was defined as p value <0.05.
Results: Overall, 80 patients were enrolled in this study. 40 of them belonged to the cisatracurium group and 40 to the atracurium group. Average age of the participants was 42.86 (±14.52) years old. Mean arterial pressure (MAP) in cisatracurium group dropped significantly following intubation (p<0.005), while it rose significantly in the atracurium group (p<0.05). However neutrophil to lymphocyte ratio (NLR) was significantly higher in the cisatracurium group following intubation (P<0.05).
Conclusion: While the use of atracurium in patients is still safe, is yet more correlated with pronounced hemodynamic instability compared to cisatracurium.
[2] Priebe H-J. Should anesthesiologists have to confirm effective facemask ventilation before administering the muscle relaxant? J Anesth. 2016; 30(1):132-7.
[3] Plaud B, Baillard C, Bourgain J-L, Bouroche G, Desplanque L, Devys J-M, et al. Guidelines on muscle relaxants and reversal in anaesthesia. Anaesth Crit Care Pain Med. 2020; 39(1):125-42.
[4] Mazur B, Greguła A, Stachyrak K, Mika D, Kłos A, Turek K, et al. Safety and side effects of suxamethonium in clinical practice – literature overview. J Education, Health and Sport. 2024; 52:11-24.
[5] Farooq K, Hunter JM. Neuromuscular blocking agents and reversal agents. Anaesthesia & intensive care medicine. 2017; 18(6):279-84.
[6] Bhagat M, Haque E, Mishra A. Safety Comparison of Cisatracurium And Atracurium In Patients Undergoing General Anaesthesia. J Anesth Clin Res. 2023; 14(3):e123-e129.
[7] Zhou DR, Eid R, Miller KA, Boucher E, Mandato CA, Greenwood MT. Intracellular second messengers mediate stress inducible hormesis and Programmed Cell Death: A review. Biochim Biophys Acta Mol Cell Res. 2019; 1866(5):773-92.
[8] Dib K, Perecko T, Jenei V, McFarlane C, Comer D, Brown V, et al. The histamine H4 receptor is a potent inhibitor of adhesion-dependent degranulation in human neutrophils. J Leukoc Biol. 2014; 96(3):411-8.
[9] Baldo BA. Toxicities of opioid analgesics: respiratory depression, histamine release, hemodynamic changes, hypersensitivity, serotonin toxicity. Arch Toxicol. 2021; 95(8):2627-42.
[10] Ghorbanlo M, Mohaghegh MR, Yazdanian F, Mesbah M, Totonchi Z. A comparison between the hemodynamic effects of cisatracurium and atracurium in patient with low function of left ventricle who are candidate for open heart surgery. Medical Archives. 2016; 70(4):265.
[11] Dahdah A, Johnson J, Gopalkrishna S, Jaggers RM, Webb D, Murphy AJ, et al. Neutrophil Migratory Patterns: Implications for Cardiovascular Disease. Front Cell Dev Biol. 2022; 10:795784.
[11] Rodríguez-Blanco J, Rodríguez-Yanez T, Rodríguez-Blanco JD, Almanza-Hurtado AJ, Martínez-Ávila MC, Borré-Naranjo D, et al. Neuromuscular blocking agents in the intensive care unit. J Int Med Res. 2022; 50(9):3000605221128148.
[12] Schramm WM, Papousek A, Michalek-Sauberer A, Czech T, Illievich U. The Cerebral and Cardiovascular Effects of Cisatracurium and Atracurium in Neurosurgical Patients. Anesth Analg. 1998; 86(1):123-7.
[13] Paśko-Majewska M, Owczuk R, Wujtewicz M. [Comparison of atracurium, cisatracurium and vecuronium during anaesthesia for laparoscopic surgery]. Anestezjol Intens Ter. 2011; 43(1):9-13.
[14] El-Kasaby AM, Atef HM, Helmy AM, El-Nasr MA. Cisatracurium in different doses versus atracurium during general anesthesia for abdominal surgery. Saudi J Anaesth. 2010; 4(3):152-7.
[15] Khobragade N, Sonwane RB. Comparative study of atracurium and cisatracurium for intubating conditions under general anaesthesia. IOSR J Dent Med Sci. 2020; 19(2):52-6.
[16] Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Cohen NH, Young WL. Miller's anesthesia e-book: Elsevier Health Sciences; 2014.
[17] Guggiari M, Gallais S, Bianchi A, Guillaume A, Viars P, editors. Hemodynamic effects of atracurium in man. Annales Francaises D'anesthesie et de Reanimation; 1985.
[18] Kale J, Mahadik HA, Korde PM. A comparative study of Atracurium and Cisatracurium for assessment of intubating conditions. IJMA. 2020; 3(3):24-7.
[19] Kaur H, ATTRI JP, Chatrath V, KAur H, Kaur J. Recovery Profile of Atracurium versus Cisatracurium. Journal of Clinical & Diagnostic Research. 2018; 12(2).
[20] Kadry RW, Adil MS, Newsome AS, Somanath PR. Cisatracurium attenuates LPS-induced modulation of MMP3 and junctional protein expression in human microvascular endothelial cells. BioScience Trends. 2021; 15(1):50-4.
[21] Fanelli V, Morita Y, Cappello P, Ghazarian M, Sugumar B, Delsedime L, et al. Neuromuscular blocking agent cisatracurium attenuates lung injury by inhibition of nicotinic acetylcholine receptor-α1. Anesthesiology. 2016;124(1):132-40.
| Files | ||
| Issue | Article in Press |
|
| Section | Research Article(s) | |
| Keywords | ||
| Neuromuscular Blocking Agents Neutrophil-to-Lymphocyte ratio General Anesthesia Demargination Migration | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
